Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

/PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug...

FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma

Y-90 resin microspheres offer a new option for liver cancer patients for the treatment of unresectable hepatocellular carcinoma.

FDA Approves Radioembolization Therapy for Unresectable Hepatocellular Carcinoma

The use of SIR-Spheres achieved a 98.5 percent overall response rate in the treatment of hepatocellular carcinoma in a recent prospective multicenter trial.

FDA Approves SIR-Spheres for Liver Cancer Treatment

The FDA approved SIR-Spheres Y-90 resin microspheres for unresectable liver cancer, the only radioembolization approved in the U.S. for both HCC and mCRC.

FDA Approves SIR-Spheres Y-90 for First-Line Use in Unresectable HCC

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.